Cover Image
市場調查報告書

男性、女性用性功能障礙治療藥市場預測 (2016-2026年):ED、派尼爾氏症、女性的性慾降低障礙、其他症狀的治療藥的開發企業的展望

Male and Female Sexual Dysfunctions - Drug Market Report and Forecasts 2016-2026: Exploring Prospects for Companies Treating Erectile Dysfunction, Peyronie's Disease, Female Hypoactive Sexual Desire Disorder and Other Conditions

出版商 Visiongain Ltd 商品編碼 346458
出版日期 內容資訊 英文 156 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
男性、女性用性功能障礙治療藥市場預測 (2016-2026年):ED、派尼爾氏症、女性的性慾降低障礙、其他症狀的治療藥的開發企業的展望 Male and Female Sexual Dysfunctions - Drug Market Report and Forecasts 2016-2026: Exploring Prospects for Companies Treating Erectile Dysfunction, Peyronie's Disease, Female Hypoactive Sexual Desire Disorder and Other Conditions
出版日期: 2015年12月07日 內容資訊: 英文 156 Pages
簡介

本報告提供男性及女性的性功能障礙治療藥的市場相關調查、性功能障礙治療方法種類與概要、藥物類別/男女的市場預測、主要治療藥及主要國家的收益預測、新的治療藥概要、研發產品線狀況、主要企業簡介、定性分析、專家的見解等彙整資料。

第1章 調查概要

第2章 性功能障礙和治療方法:簡介

  • 診斷標準:ICD-10、DSM-V
  • 男性性功能障礙
    • 性慾障礙
    • ED
    • 陰莖反常勃起
    • 派尼爾氏症
    • 早洩性障礙
    • 性功能降低
  • 女性性功能障礙
    • 性興奮障礙
    • 持續性興奮症候群
    • 性高潮功能障礙
    • 性交疼痛
    • 外陰系統疾病

第3章 全球性功能障礙治療藥市場預測

  • 全球市場的預測
  • 各類藥物
    • PDE5抑制劑:依然保持最大的佔有率
    • Prostaglandins:Alprostadils具壟斷性
    • Androgens:新投藥技術的推動可能性
    • Gonadotrophins:新產品預定上市
    • 預計其他藥劑級:大幅成長
  • 男女
    • 男性:由於首發藥的專利保護到期而有降低趨勢
    • 女性:預計新興國家有確實成長可能性

第4章 性功能障礙治療藥:收益預測

  • Cialis (Eli Lilly)
  • Viagra (Pfizer)
  • Gonal-F (Merck KGaA)
  • Puregon (Merck & Co.)
  • Decapeptyl SR (Ipsen Ltd)
  • Caverject Dual Chamber (Pfizer)
  • Levitra (Bayer)
  • Nebido (Bayer)
  • Testim (Ferring Pharmaceuticals)
  • Priligy (J&J/A. Menarini Pharma UK SRL)
  • Stendra/Spedra (VIVUS/Endo/Auxilium Pharmaceuticals)
  • MUSE (Meda Pharmaceuticals)
  • Viridal Duo/Edex (UCB Pharma/Auxilium Pharmaceuticals)
  • Tostran (ProStrakan Pharmaceuticals)
  • Vitaros (武田藥品工業)
  • Restandol Testocaps (Merck & Co.)
  • Sustanon 250 (Aspen Pharma Trading)
  • Bemfola (Finox Biotech UK & Ireland Ltd.)
  • Menopur (Ferring Pharmaceuticals)
  • Pregnyl (Merck & Co.)
  • Androcur (Bayer Plc)
  • Gonapeptyl (Ferring Pharmaceuticals)
  • Intrinsa (Procter & Gamble)

第5章 性障礙新的治療藥

  • Vitaros (武田藥品工業)
  • Addyi (Sprout/Valeant Pharmaceuticals)
  • Xiapex (Auxilium Pharmaceuticals)

第6章 主要企業

  • Eli Lilly
  • Pfizer
  • Merck KGaA
  • Merck & Co.
  • Ipsen Ltd
  • Bayer

第7章 主要國家市場:收益預測

  • 美國
  • 日本
  • 歐盟5國
  • 金磚四國
  • 其他地區

第8章 研發產品線

  • 男性性功能障礙治療藥的研發產品線
    • Tissue Genesis Cell Isolation System (Tissue Genesis, Inc.):ED
    • Adipose-Derived Stem Cell Injection (Ageless Regenerative Institute):ED
    • Selegiline (University of South Florida):ED
    • VL#FIA3-30 (VasoLead):ED
    • MED2002 (Futura Medical):ED
    • MED2005 (Futura Medical Developments Ltd):ED
    • Fispemifene (NexMed):ED、連續發生性性功能降低症
    • Transdermal Androgel (Johns Hopkins University):puriapisumu
    • Adipose Tissue Stem Cell Injection (Man Clinic for Andrology, Male Infertility and Sexual Dysfunction):派尼爾氏症
    • AA4500、ErecAid Esteem Manual Vacuum Therapy System (Endo Pharmaceuticals):派尼爾氏症
    • H-22411(Allergan):派尼爾氏症
    • AA4500 (Allergan):派尼爾氏症
    • IX-01 (Ixchelsis Limited):早洩性障礙
    • CDFR0812-15 (CTC Bio, Inc.):早洩性障礙
  • 女性性功能障礙治療藥的研發產品線:新的治療藥
    • Tribulus Terrestris:女性性慾降低障礙
    • Bremelanotide (Palatin Technologies):女性性慾降低障礙
    • Lybridos (Emotional Brain NY Inc.):女性性慾降低障礙
    • Lorexys (S1 Biopharma):女性性慾降低障礙
    • SST-6007 (Strategic Science & Technologies, LLC):女性性慾降低障礙
    • TBS-2 (Acerus Pharmaceuticals Corporation):性高潮
    • SST-6006 (Strategic Science & Technologies, LLC):女性性功能障礙
    • Fluocinonide Cream (OHSU Knight Cancer Institute National Cancer Institute (NCI):性交疼痛)

第9章 定性分析

  • SWOT分析
  • STEP分析

第10章 專家的採訪

  • Carl Spana博士、Stephen Wills (Palatin Technologies)
  • James Barder (CEO, Futura Medical)

第11章 總論

圖表

目錄
Product Code: PHA0081

Sexual Dysfunction Drugs - New Study Exploring Potentials of Established and Recently Approved Drugs, Industry Changes and Emerging Opportunities

Are you interested in the future of treatments for sexual disorders? Our new analysis forecasts drug revenues for male and female treatments. There you explore sales results, R&D and opportunities, seeing changing trends and commercial prospects.

Discover, from 2015, progress, opportunities and revenues. Drugs our study covers include treatments for erectile dysfunction (ED), Peyronie's disease and female hypoactive sexual desire disorder (HSDD). See the effect of recent drug approvals.

Please read on to explore that industry and see what future revenue it could generate.

Predictions and other analysis to benefit your research, plans and decisions

Visiongain's report gives revenue predictions to 2026 at overall world market, submarket, product and national level. Avoid falling behind in data or losing influence.

The future holds promise for pharma companies treating sexual dysfunction. New products enter that market and clinical testing shows commercial potential, especially for HSDD. Discover, from 2015, what revenues and other progress are possible.

Besides revenue forecasting to 2026, our new work shows recent results and market shares. There you find original analysis. You assess research and development too. Also gain 48 tables, 55 charts and two interviews with companies.

Forecasts covering the overall world market and segments for sexual disorder treatments

Discover in our new analysis revenue predictions to 2026 for four drug classes at world level. See what is possible for these submarkets:

  • PDE5 inhibitors
  • Prostaglandins
  • Androgens
  • Gonadotrophins
  • Other drug classes (grouped).

Our work also divides the overall world market into revenues for male and female treatments.

With our survey you assess outlooks for revenue expansion, seeing where you can gain. You also investigate competitors' actions, technologies and outlooks.

That way you see how those genitourinary medicines develop. You discover where needs and business opportunities exist. With a rising incidence of sexual disorders, the demand for better treatments will continue to enrich the pharmaceutical industry.

Our study also explores sales forecasts by product, showing how those agents can perform. See what gains are possible.

Predictions of leading products' sales - what is possible for that industry's top drugs?

How will individual sexual disorder medicines perform from 2015 to 2026 at world level? Our study gives 14 product-level forecasts, including for these brands:

  • Cialis
  • Viagra
  • Gonal-F
  • Levitra
  • Nebido
  • Testim
  • Priligy
  • Tostran

The report also assesses emerging therapies: Vitaros, Addyi and Xiapex.

With that analysis you hear how high sales can go, finding products and years with highest predicted revenues. You also examine competition. Explore challenges, trends, competitors and opportunities.

Our work also shows you geographical predictions by leading country.

National markets - what outlooks for those sexual medicine revenues?

Our work shows you individual revenue forecasts to 2026 for 11 national markets:

  • US
  • Japan
  • Germany, France, UK, Spain, Italy (EU5)
  • Brazil, Russia, India, China (BRIC)
  • Rest of world (grouped analysis).

Visiongain forecasts that BRIC countries will show the fastest growth and account for 17% of the overall world market by 2026. The rise of that region's sales will be driven, in particular, by revenues in China and India.

The recent FDA approval of Addyi (flibanserin), for hypoactive sexual desire disorder, gives a breakthrough for female sexual dysfunction treatment. Suppliers of therapies will take encouragement from that development serving a large, emerging need.

Our report also shows trends leading to novel and improved treatments, forces changing that market.

Events and changes affecting companies treating sexual disorders

Explore other issues, too, including influences and treatment needs shaping that industry and market:

  • Male sexual problems - erectile dysfunction, priapism, Peyronie's disease, premature ejaculation, hypogonadism
  • Female sexual disorders - HSDD, difficulty achieving orgasm, persistent sexual arousal syndrome, sexual pain, dyspareunia, vaginismus, vulvodynia
  • Drug approvals for Peyronie's disease and female sexual dysfunction
  • Developments in diagnosis, reporting of difficulties to doctors and willingness to treat those conditions
  • Research and development for male and female therapies, including advances in drug delivery.

Our study also gives SWOT and STEP analyses, exploring what drives and restrains that prominent, developing market.

See, then, what is possible for leading pharma companies and specialist firms.

Leading organisations and overall 2019 market value - what revenues are possible? Our work predicts the world market for those drugs will reach $7.7bn in 2019. That industry will achieve revenue expansion from 2015 to 2026. With our analysis you discover how high sales can go. Assess the gains possible.

For sexual disorder therapies you also explore the industry's leading companies. They include Eli Lilly, Pfizer, Merck KGaA, Merck & Co., Ipsen and Bayer.

You also gain exclusive interviews with Palatin Technologies and Futura Medical. Discover what the future holds for companies in that market.

7 ways Male and Female Sexual Dysfunctions: Drug Market Report and Forecasts 2016-2026 helps you

Our new investigation benefits your work in these seven main ways, helping you stay ahead in knowledge:

  • Revenues for sexual dysfunction drug therapies to 2026 - assess that overall world market's potential, seeing scope for investments, developments, production and marketing
  • Submarket revenues to 2026 covering four therapeutic segments - explore treatment categories, seeing their sales outlooks from 2015
  • Leading products' sales to 2026 - discover predicted revenues of 14 top brands, assessing how those medicines can compete and succeed
  • Forecasting to 2026 for 11 countries in the Americas, Europe and Asia - explore the best regions for treatment demand, sales and revenue growth
  • R&D activities - see progress, trends and prospects in that research and development, finding technological, clinical and commercial possibilities
  • Companies, news and opinion - examine participants in that progressing market, gaining insight to help you stay ahead and benefit your influence
  • Analysis of what stimulates and restrains that market - assess challenges and strengths there, helping you compete and gain advantages.

That analysis, by our in-house team in the UK, benefits anyone exploring that market. It shows data you find nowhere else, helping you succeed.

Gain predictions for treating sexual dysfunction, staying ahead

With our independent study you explore products, companies, progress and possibilities. Discover what the future holds for that market and its companies.

Having that information means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how to save time and effort, also benefiting your plans, decisions, presentations, proposals and authority.

Our investigation shows data, trends, opportunities and forecasts for that expanding pharma market. So avoid missing out - please get our new report here now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of the World Market for Sexual Dysfunctions Treatment
  • 1.2. Why You Should Read This Report
  • 1.3. How This Study Delivers
  • 1.4. Main Questions Answered by this Analysis
  • 1.5. Who is this Report For?
  • 1.6. Methods of Research and Analysis
  • 1.7. Frequently Asked Questions (FAQs)
  • 1.8. Some Associated Reports
  • 1.9. About Visiongain

2. Introduction to Sexual Dysfunctions and Treatment Options

  • 2.1. Diagnosis-ICD-10 and DSM-V
  • 2.2. Male Sexual Dysfunctions
    • 2.2.1. Sexual Desire Dysfunctions
    • 2.2.2. Erectile Dysfunction
    • 2.2.3. Priapism
    • 2.2.4. Peyronie's Disease
    • 2.2.5. Premature Ejaculation
    • 2.2.6. Hypogonadism
  • 2.3. Female Sexual Dysfunctions
    • 2.3.1. Dysfunctions of Arousal
    • 2.3.2. Persistent Sexual Arousal Syndrome
    • 2.3.3. Dysfunctions of Orgasm
    • 2.3.4. Sexual Pain Dysfunctions
  • 2.3.4.1. Dyspareunia
  • 2.3.4.2. Vaginismus
    • 2.3.5. Vulvodynia

3. The World Sexual Dysfunctions Drugs Market, 2015-2026

  • 3.1. Global Sexual Dysfunctions Drugs Forecast 2015-2026
  • 3.2. Sexual Dysfunction Drugs Market by Drug Class
    • 3.2.1. PDE5 Inhibitors-Still Hold the Biggest Market Share
    • 3.2.2. Prostaglandins-Dominated by Alprostadils
    • 3.2.3. Androgens-Will New Delivery Technology Drive This Submarket?
    • 3.2.4. Gonadotrophins-New Products Launched Expected
    • 3.2.5. Other Drug Classes Market-Will See Significant Growth
  • 3.3. Sexual Dysfunctions Drugs Market by Gender
    • 3.3.1. Male Sexual Dysfunctions Drugs Market 2015-2026-Declining as Originator Drugs Lose Patent Protection
    • 3.3.2. Female Sexual Dysfunctions Drugs Market 2015-2026-a Developing Market Holding Promising Commercial Potential

4. Sexual Dysfunction-Treating Drugs: Revenue Forecasts, 2015-2026

  • 4.1. Cialis (Eli Lilly)-Faces Patent Expiry
  • 4.2. Viagra (Pfizer)-Will Extended Patent in the US Protect Revenue?
  • 4.3. Gonal-F (Merck KGaA)-Slow Growth in the First Half of the Forecast Period
  • 4.4. Puregon (Merck & Co.)-Expected to Decline Significantly
  • 4.5. Decapeptyl SR (Ipsen Ltd)-Growing Until the End of the First Half of the Forecast Period
  • 4.6. Caverject Dual Chamber (Pfizer)-Growing During the First Half of the Forecast Period
  • 4.7. Levitra (Bayer)-Sales Eroded by Cheaper PDE5 Inhibitors?
  • 4.8. Nebido (Bayer)-Intramuscular Formulation of Testosterone Undecanoate
  • 4.9. Testim (Ferring Pharmaceuticals)-Differentiated by Consistent Transdermal Absorption
  • 4.10. Priligy (J&J/A. Menarini Pharma UK SRL)-SSRI to Treat Premature Ejaculation
  • 4.11. Stendra/Spedra (VIVUS/Endo/Auxilium Pharmaceuticals)-Newest PDE5 Inhibitor
  • 4.12. MUSE (Meda Pharmaceuticals)-Suppository Prostaglandin
  • 4.13. Viridal Duo/Edex (UCB Pharma/Auxilium Pharmaceuticals)-Growing Strongly in the First Half of the Forecast Period
  • 4.14. Tostran (ProStrakan Pharmaceuticals)-Eroded by Generic Competition Since 2014
  • 4.15. Vitaros (Takeda)-Topical Formulation of Alprostadil
  • 4.16. Restandol Testocaps (Merck & Co.)-Testosterone Replacement
  • 4.17. Sustanon 250 (Aspen Pharma Trading)-Preferred Testosterone Replacement in the UK
  • 4.18. Bemfola (Finox Biotech UK & Ireland Ltd.)-Biosimilar
  • 4.19. Menopur (Ferring Pharmaceuticals)-a Preparation of Gonadotrophins
  • 4.20. Pregnyl (Merck & Co.)-to Treat Hypogonadism
  • 4.21. Androcur (Bayer Plc)-to Treat Androgen-related Conditions
  • 4.22. Gonapeptyl (Ferring Pharmaceuticals)-Depot Injection
  • 4.23. Intrinsa (Procter & Gamble)-Testosterone Patch

5. Emerging Therapies for Sexual Disorders

  • 5.1. Vitaros (Takeda)-Topical Cream to Treat Erectile Dysfunction
  • 5.2. Addyi (Sprout/Valeant Pharmaceuticals)-First Approved Drug for Female Sexual Dysfunction
  • 5.3. Xiapex (Auxilium Pharmaceuticals)- First Approved Drug for Peyronie's Disease

6. Leading Companies in the Sexual Dysfunction Drugs Market

  • 6.1. Eli Lilly-Leading With Cialis
  • 6.2. Pfizer-Will It Overtake Eli Lilly in This Forecast Period?
  • 6.3. Merck KGaA-Driven by Sales in Emerging Markets
  • 6.4. Merck & Co.-Will It Soon Lose Its Share to Competitors?
  • 6.5. Ipsen Ltd-Ongoing Clinical Trials for Decapeptyl May Drive Further Growth
  • 6.6. Bayer-Orodispersible Form of Levitra Not Pushing Revenue?

7. Leading National Markets: Revenue Forecasts, 2015-2026

  • 7.1. The US Sexual Dysfunctions Drugs Market, 2015-2026-Leader of the Pack
  • 7.2. The Japanese Sexual Dysfunctions Drugs Market, 2015-2026-Still Driven by Viagra and Cialis Sales
  • 7.3. EU5 Sexual Dysfunctions Drugs Market, 2015-2026-Cost Containment Will Slow the Market
  • 7.4. BRIC Sexual Dysfunctions Drugs Market, 2015-2026-Driven by Growth in China and India
  • 7.5. Other Regions' Sexual Dysfunctions Drugs Market, 2015-2026-Expected High Growth Rate

8. R&D Pipelines for Sexual Dysfunctions Treatment

  • 8.1. R&D Pipeline Drugs for Male Sexual Dysfunctions-Still Dominated by ED
    • 8.1.1. Tissue Genesis Cell Isolation System (Tissue Genesis, Inc.)-ED
    • 8.1.2. Adipose-Derived Stem Cell Injection (Ageless Regenerative Institute)-ED
    • 8.1.3. Selegiline (University of South Florida)-ED
    • 8.1.4. VL#FIA3-30 (VasoLead)-ED
    • 8.1.5. MED2002 (Futura Medical)-ED
    • 8.1.6. MED2005 (Futura Medical Developments Ltd) - ED
    • 8.1.7. Fispemifene (NexMed)-ED and Secondary Hypogonadism
    • 8.1.8. Transdermal Androgel (Johns Hopkins University)-Priapism
    • 8.1.9. Adipose Tissue Stem Cell Injection (Man Clinic for Andrology, Male Infertility and Sexual Dysfunction)-Peyronie's Disease
    • 8.1.10. AA4500 and ErecAid Esteem Manual Vacuum Therapy System (Endo Pharmaceuticals)-Peyronie's Disease
    • 8.1.11. H-22411(Allergan)-Peyronie's Disease
    • 8.1.12. AA4500 (Allergan) - Peyronie's Disease
    • 8.1.13. IX-01 (Ixchelsis Limited) - Premature Ejaculation
    • 8.1.14. CDFR0812-15 (CTC Bio, Inc.)-Premature Ejaculation
  • 8.2. R&D Pipeline Drugs for Female Sexual Dysfunctions-Emerging Therapies
    • 8.2.1. Tribulus Terrestris-Female Hypoactive Sexual Desire Disorder
    • 8.2.2. Bremelanotide (Palatin Technologies)-Female Hypoactive Sexual Desire Disorder
    • 8.2.3. Lybridos (Emotional Brain NY Inc.)-Female Hypoactive Sexual Desire Disorder
    • 8.2.4. Lorexys (S1 Biopharma) - Female Hypoactive Sexual Desire Disorder
    • 8.2.5. SST-6007 (Strategic Science & Technologies, LLC) - Female Hypoactive Sexual Desire Disorder
    • 8.2.6. TBS-2 (Acerus Pharmaceuticals Corporation)-Orgasmic Disorder
    • 8.2.7. SST-6006 (Strategic Science & Technologies, LLC)-Female Sexual Dysfunction
    • 8.2.8. Fluocinonide Cream (OHSU Knight Cancer Institute National Cancer Institute (NCI))-Painful Sexual Intercourse

9. Qualitative Analysis of the Sexual Dysfunctions Drugs Market 2015-2026

  • 9.1. SWOT Analysis of the Sexual Dysfunctions Drugs Market, 2015-2026
    • 9.1.1. Strengths
    • 9.1.2. Weaknesses
    • 9.1.3. Opportunities
    • 9.1.4. Threats
  • 9.2. STEP Analysis of the Sexual Dysfunctions Drugs Market, 2015-2026
    • 9.2.1. Social
    • 9.2.2. Technological
    • 9.2.3. Economic
    • 9.2.4. Political

10. Research Interviews from Our Survey-2015

  • 10.1. Dr. Carl Spana and Mr. Stephen Wills, Palatin Technologies
    • 10.1.1. Palatin Technologies, Inc.
    • 10.1.2. Female Sexual Dysfunction Market-What Are the Challenges?
    • 10.1.3. Industry Effort to Bridge the Gaps
    • 10.1.4. Drivers and Restraints of the FSD Market
    • 10.1.5. Bremelanotide-On-Demand Treatment for HSDD
    • 10.1.6. Designing Clinical Trials to Assess Drugs for FSDs-Remains a Challenge?
    • 10.1.7. Commercial Potential of Bremelanotide
  • 10.2. James Barder, CEO, Futura Medical
    • 10.2.1. Futura Medical
    • 10.2.2. Will the ED Treatment Market Show Growth?
    • 10.2.3. Unmet Needs of ED Treatment and Management
    • 10.2.4. MED2002 for ED - Targeted Delivery
    • 10.2.5. DermaSys-Improves Permeation of APIs through the Skin
    • 10.2.6. DermaSys -Therapeutic Benefits to Other Therapeutic Areas?
    • 10.2.7. MED2002-Could Potentially Meet the Unmet Demand in ED

11. Conclusions

  • 11.1. Male Sexual Dysfunction Drugs Market
  • 11.2. Female Sexual Dysfunction Drugs Market
  • 11.3. Leading National Markets
  • 11.4. Drugs in the Pipeline

List of Tables

  • Table 1.1: Global Sexual Dysfunction Drugs Market: Regional and National Submarket Revenue Forecasts ($bn), 2015-2026
  • Table 3.1: Global Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 3.2: Global Sexual Dysfunction Drugs Market Revenue by Drug Class: Forecasts ($bn), 2015-2026
  • Table 3.3: Global PDE5 Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 3.4: Global Prostaglandins Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 3.5: Global Androgens Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 3.6: Global Gonadotrophins Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 3.7: Global Other Drug Classes Market: Grouped Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 3.8: Global Sexual Dysfunction Drugs Market by Drug Class: Submarket Shares (%), 2015-2026
  • Table 3.9: Global Sexual Dysfunction Drugs Market Revenue by Gender: Forecasts ($bn), 2015-2026
  • Table 3.10: Global Male Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 3.11: Global Female Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 3.12: Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2015-2026
  • Table 4.1: Leading Sexual Dysfunction Drugs by Revenue ($bn), 2014
  • Table 4.2: Cialis Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.3: Viagra Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.4: Gonal-F Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.5: Puregon Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.6: Decapeptyl Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.7: Caverject Dual Chamber Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.8: Levitra Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.9: Nebido Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.10: Testim Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.11: Priligy Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.12: Stendra/Spedra Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.13: MUSE Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.14: Viridal Duo/Edex Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.15: Tostran Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.16: Leading Sexual Dysfunction Drugs, Market Shares (%), 2015-2026
  • Table 6.1: Top Companies for Sexual Dysfunction Drugs: Revenues ($bn) and Market Shares (%), 2014
  • Table 6.2: Eli Lilly- Revenue ($bn) and Share (%), 2014
  • Table 6.3: Pfizer- Revenue ($bn) and Share (%), 2014
  • Table 6.4: Merck KGaA- Revenue ($bn) and Share (%), 2014
  • Table 6.5: Merck & Co. - Revenue ($bn) and Share (%), 2014
  • Table 6.6: Ipsen Ltd - Revenue ($bn) and Share (%), 2014
  • Table 6.7: Bayer - Revenue ($bn) and Share (%), 2014
  • Table 7.1: Global Sexual Dysfunction Drugs Market: National Submarket Revenue Forecasts ($bn), 2015-2026
  • Table 7.2: Grouped Global Sexual Dysfunction Drugs Market: Regional Submarket Revenue Forecasts ($bn), 2015-2026
  • Table 7.3: US Sexual Dysfunction Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 7.4: Japanese Sexual Dysfunction Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 7.5: EU5 Sexual Dysfunction Drugs Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 7.6: BRIC Sexual Dysfunction Drugs Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 7.7: Other Regions' Sexual Dysfunction Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 8.1: List of Selected Drug Candidates for Male Sexual Dysfunctions
  • Table 8.2: List of Selected Drug Candidates for Female Sexual Dysfunctions
  • Table 9.1: Strengths, Weaknesses, Opportunities and Threats in the Sexual Dysfunction Drugs Market, 2015
  • Table 9.2: Social, Technological, Economic and Political Analysis of the Sexual Dysfunction Drugs Market, 2015
  • Table 11.1: Global Sexual Dysfunction Revenue Forecasts ($bn), CAGR (%) and Market Share (%) by Product Category, 2014, 2020, 2026
  • Table 11.2: Global Sexual Dysfunction Revenue Forecasts ($bn), CAGR (%) and Market Shares (%) by Region, 2014, 2020, 2026

List of Figures

  • Figure 3.1: The Global Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026
  • Figure 3.2: Global PDE5 Market: Revenue Forecast ($bn), 2015-2026
  • Figure 3.3: Global Prostaglandins Market: Revenue Forecast ($bn), 2015-2026
  • Figure 3.4: Global Androgens Market: Revenue Forecast ($bn), 2015-2026
  • Figure 3.5: Global Gonadotrophins Market: Revenue Forecast ($bn), 2015-2026
  • Figure 3.6: Global Other Drug Classes Market: Grouped Revenue Forecast ($bn), 2015-2026
  • Figure 3.7: Global Sexual Dysfunction Drugs Market by Drug Class: Revenue Forecasts ($bn), 2015-2026
  • Figure 3.8: Global Sexual Dysfunction Drugs Market by Drug Class: Submarket Share (%), 2015-2026
  • Figure 3.9: Global Male Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026
  • Figure 3.10: Global Female Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026
  • Figure 3.11: Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2014
  • Figure 3.12: Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2020
  • Figure 3.13: Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2026
  • Figure 3.14: Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2015-2026
  • Figure 3.15: Global Sexual Dysfunction Drugs Market: Submarket Forecasts ($bn), 2015-2026
  • Figure 4.1: Cialis Revenue Forecast ($bn), 2015-2026
  • Figure 4.2: Viagra Revenue Forecast ($bn), 2015-2026
  • Figure 4.3: Gonal-F Revenue Forecast ($bn), 2015-2026
  • Figure 4.4: Puregon Market Forecast ($bn), 2015-2026
  • Figure 4.5: Decapeptyl Market Forecast ($bn), 2015-2026
  • Figure 4.6: Caverject Dual Chamber Market Forecast ($bn), 2015-2026
  • Figure 4.7: Levitra Revenue Forecast ($bn), 2015-2026
  • Figure 4.8: Nebido Revenue Forecast ($bn), 2015-2026
  • Figure 4.9: Testim Revenue Forecast ($bn), 2015-2026
  • Figure 4.10: Priligy Revenue Forecast ($bn), 2015-2026
  • Figure 4.11: Stendra/Spedra Market Forecast ($bn), 2015-2026
  • Figure 4.12: MUSE Revenue Forecast ($bn), 2015-2026
  • Figure 4.13: Viridal Duo/Edex Revenue Forecast ($bn), 2015-2026
  • Figure 4.14: Tostran Revenue Forecast ($bn), 2015-2026
  • Figure 4.15: Leading Sexual Dysfunction Drugs, Market Shares (%), 2015-2026
  • Figure 6.1: Top Producers of Sexual Dysfunction Drugs: Market Shares (%), 2014
  • Figure 6.2: Eli Lilly's Drugs by Share of Company Revenue (%), 2014
  • Figure 6.3: Pfizer's Drugs by Share of Company Revenue (%), 2014
  • Figure 6.4: Merck KGaA's Drugs by Share of Company Revenue (%), 2014
  • Figure 6.5: Merck & Co.'s Drugs by Share of Company Revenue (%), 2014
  • Figure 6.6: Ipsen Ltd.'s Drugs by Share of Company Revenue (%), 2014
  • Figure 6.7: Bayer's Drugs by Share of Company Revenue (%), 2014
  • Figure 7.1: Global Sexual Dysfunction Drugs Market: Regional Submarket Revenue Forecasts ($bn), 2015-2026
  • Figure 7.2: Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2014
  • Figure 7.3: Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2020
  • Figure 7.4: Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2026
  • Figure 7.5: Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2014-2026
  • Figure 7.6: US Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026
  • Figure 7.7: Japanese Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026
  • Figure 7.8: EU5 Sexual Dysfunction Drugs Market: Revenue Forecasts ($bn), 2015-2026
  • Figure 7.9: EU5 Sexual Dysfunction Drugs Market: Submarket Shares (%), 2014
  • Figure 7.10: EU5 Sexual Dysfunction Drugs Market: Submarket Shares (%), 2020
  • Figure 7.11: EU5 Sexual Dysfunction Drugs Market: Submarket Shares (%), 2026
  • Figure 7.12: EU5 Sexual Dysfunction Drugs Market: Submarket Shares (%), 2015-2026
  • Figure 7.13: BRIC Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026
  • Figure 7.14: BRIC Sexual Dysfunction Drugs Market: Submarket Shares (%), 2014
  • Figure 7.15: BRIC Sexual Dysfunction Drugs Market: Submarket Shares (%), 2020
  • Figure 7.16: BRIC Sexual Dysfunction Drugs Market: Submarket Shares (%), 2026
  • Figure 7.17: BRIC Sexual Dysfunction Drugs Market: Submarket Shares (%), 2015-2026
  • Figure 7.18: Other Regions' Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026

Companies Listed

  • A. Menarini Pharma UK SRL
  • Acerus Pharmaceuticals Corporation
  • Actavis
  • Ageless Regenerative Institute
  • Allergan
  • American Psychiatric Association
  • Apotex Corp.
  • Apotex Inc.
  • Aspen Pharma Trading
  • Auxilium Pharmaceuticals
  • Bayer
  • Besins Healthcare UK
  • Cipla
  • CTC Bio, Inc.
  • Eli Lilly
  • EMA
  • Emotional Brain NY Inc.
  • Endo Pharmaceuticals
  • FDA
  • Federal University of Minas Gerais
  • Ferring Pharmaceuticals
  • Finox Biotech UK & Ireland
  • Futura Medical
  • Glennwood, GmbH
  • Hetero Labs Limited
  • Ipsen Ltd.
  • Ixchelsis
  • Johns Hopkins University
  • Johnson & Johnson
  • Man Clinic for Andrology, Male Infertility and Sexual Dysfunction
  • Meda Pharmaceuticals
  • Merck & Co.
  • Merck KGaA
  • Mylan Pharmaceuticals
  • NexMed
  • OHSU Knight Cancer Institute
  • Palatin Technologies
  • Pfizer
  • Pharmasure
  • Procter & Gamble
  • ProStrakan Pharmaceuticals
  • S1 Biopharma
  • Sprout Pharmaceuticals
  • Strategic Science & Technologies LLC
  • Swedish Orphan Biovitrum Ltd (SOBI)
  • Takeda
  • Tissue Genesis, Inc.
  • UCB
  • Unimed Pharmaceuticals
  • University of South Florida
  • Valeant Pharmaceuticals
  • VasoLead
  • VIVUS
  • Watson Pharmaceuticals
  • World Health Organization (WHO)
Back to Top